Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
about
Maintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: two case reports and literature review.Prolonged complete response after treatment withdrawal in HER2-overexpressed, hormone receptor-negative breast cancer with liver metastases: the prospect of disappearance of an incurable disease.New developments in the treatment of metastatic gastric cancer: focus on trastuzumabTrastuzumab in advanced breast cancer--a decade of experience in GermanyTrastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience.Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence?Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.Drug rechallenge and treatment beyond progression--implications for drug resistance.Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy.Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experienceClinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapiesChemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on first-line therapy predicts overall survival impact.Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.Living Well? Strategies Used by Women Living With Metastatic Breast Cancer.Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer.Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer.The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma.Treatment beyond progression: is it moving from belief to evidence?Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities.Positive spillover effects of prescribing requirements: increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer.Trastuzumab beyond progression in advanced breast cancer: national guidance versus oncologist's decision.Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.Trastuzumab (herceptin): a retrospective analysis of the effects of long-term application in a series of patients with breast cancer.HER2 Positive Bilateral Metachronous Primary Breast Carcinoma: A Case Report.Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer.Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy.
P2860
Q34130140-2EB871FF-16DC-4E1E-A3BD-488830D505CBQ34565743-2A35417C-A56E-439E-81D6-1943869E9625Q34883258-8F55C7BF-D9CC-4FAD-A12B-40C93AE8AB2FQ34969710-F6CB312D-75BC-46DF-9191-F0F3920E253FQ35034559-1C863B20-63B3-4B5B-98D5-C70DA33A5F82Q35584899-26C871B0-3B62-4B00-A881-2268B1154D4AQ35880224-B07D146B-6B31-4C64-BFAD-BC6AA9E06D1FQ35967416-38BBAF54-048B-45F6-93AD-D9DF9BFE3033Q36779798-5BBA1BA3-27E0-42DB-8B4B-75ED6B82D3C6Q37100311-CBEB17CE-D2D1-4F0B-B2AF-7C19CE83D8E0Q37172361-018BF83C-A1B5-436B-B9BD-B1A24FEBF488Q37236305-93F09B19-0A89-46E0-8EF6-2073E4A944A8Q37241496-217867FF-E180-4A8E-A9F1-3D05E300A42BQ37301477-200A616E-DFFE-42A7-BE98-80E86A089A07Q37534928-04CCD174-3618-4B80-B98A-525B856915BDQ37580446-05F985E6-752E-45BC-91DD-A301E775FAF5Q38119307-17A400CB-A3A6-4DE3-9879-1F68EAFE632EQ38225376-CAD1DE38-9305-4B85-BDB3-3118CB092CE7Q38289356-73A172CD-492B-42C2-8012-0AC17D594FF7Q38989482-E2BAB528-C379-45EE-9C91-BDB88439CE76Q39656542-77B0DC19-8864-44A2-B1B5-EB86D3FD5AF0Q39748463-6469821B-528F-4C9D-920D-D5ED4B100701Q41972324-547E653C-7D2B-477A-840E-A8F2204E344DQ42995231-3FF5E056-A1FD-413F-B42B-7013882ABA5DQ42995515-66481323-83FD-4EAA-ABEF-7DB8ED8CF61AQ45735095-B6882C05-5D69-492B-995D-89FB627BD3F7Q46002138-C74375F0-F516-4D6E-9EE0-A858FC16D5D6Q46074968-A147A00B-6E0C-4DA8-BF09-E5F8ECA1015BQ46958045-90B2AE98-C433-46D2-B3F5-7A4D845ADE52Q50047680-24F60C80-DC7A-4C5B-B7E8-FC863EE446E7Q52150386-77914E32-6D93-4D9B-BFA4-886CE9EF02BFQ53175758-83F949F4-4879-4C02-9240-55A82DC426E3Q54368881-57A58440-B70A-4EB2-9C93-93D169243AECQ54591190-BD2BBC23-37B2-4B1F-98E4-819126475FBEQ55067446-290D687E-2C7D-4D60-95B6-1042D81F81A8
P2860
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Efficacy of trastuzumab in rou ...... e observational Hermine study.
@ast
Efficacy of trastuzumab in rou ...... e observational Hermine study.
@en
type
label
Efficacy of trastuzumab in rou ...... e observational Hermine study.
@ast
Efficacy of trastuzumab in rou ...... e observational Hermine study.
@en
prefLabel
Efficacy of trastuzumab in rou ...... e observational Hermine study.
@ast
Efficacy of trastuzumab in rou ...... e observational Hermine study.
@en
P2093
P2860
P1433
P1476
Efficacy of trastuzumab in rou ...... e observational Hermine study.
@en
P2093
Anne Bethune-Volters
Christophe Hebert
Céline Remblier
Daniel Serin
Eric C Antoine
Frank Campana
Jean-Louis Misset
Jean-Marc Extra
Jean-Paul Guastalla
Louis Mauriac
P2860
P304
P356
10.1634/THEONCOLOGIST.2009-0029
P577
2010-07-29T00:00:00Z